TABLE 1.
Mean Times Spent in TWiST, TOX, and REL With Cabozantinib and Sunitinib
| Treatment | No. | Mean (SE), Days | Difference Between Cabozantinib Versus Sunitinib | ||
|---|---|---|---|---|---|
| Mean (SE), Days | 95% CI | ||||
| TWiST | Cabozantinib | 79 | 317 (29) | 137 (39) | 60 to 214 |
| Sunitinib | 78 | 180 (26) | |||
| TOX | Cabozantinib | 79 | 31 (4) | −8 (9) | −25 to 9 |
| Sunitinib | 78 | 39 (8) | |||
| REL | Cabozantinib | 79 | 154 (36) | −105 (51) | −206 to −5 |
| Sunitinib | 78 | 259 (36) | |||
Abbreviations: 95% CI, 95% confidence interval; REL, time after disease recurrence (relapse) or progression to death; SE, standard error; TOX, time with toxicity before disease progression; TWiST, time without symptoms of disease and without toxicity.
Mean times spent in TWiST, TOX, and REL states (prior to utility weighting) were estimated using partitioned Kaplan‐Meier survival curves. Durations of adverse events were based on the A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR) trial 11 for cabozantinib or the study by Patil et al 19 for the sunitinib group.